Femasys begins enrollment for FemBloc trial

Femasys announced that it has activated enrollment for its FemBloc trial at University of California, Davis Medical Center in Sacramento, California. The FemBloc Intratubal Occlusion for TranscervicAL Permanent Birth Control is being conducted to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc. The FDA-approved, multi-center trial is designed to address the high unmet need that exists for women seeking permanent birth control, for whom elective surgery currently remains the only option. “UC Davis Medical Center, a nationally renowned medical center, is another great addition to the clinical trial sites participating in this initial phase of the FINALE trial, as Dr. Mitchell Creinin has been a long-time supporter of our new permanent birth control option,” said Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys.